Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.285 EUR
156.92 M EUR
7.21 B EUR
277.91 M
About GRIFOLS S.A.
Sector
Industry
CEO
Nacho Abia
Website
Headquarters
Barcelona
Founded
1940
ISIN
ES0171996087
FIGI
BBG00NL2SW73
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Related stocks
Buy $GRFS - NRPicks 11 MarGrifols, S.A. engages in the acquisition, manufacture, preparation and sale of therapeutic products, principally plasma derivatives. The company operates through the Bioscience, Hospital, Diagnostics, Bio Supplies and Others segments.
Revenue TTM 5.6B
Net Income TTM 208M
EBITDA TTM 894M
EBITDA mar
Are we at the bottom yet?Grifols stock has been heavely punished during 2021.
First the pandemic difficulted the plasma collection. We must take into account the stimulus checks and the unemployment benefits from the US goverment wich might have disuaded people from going to the plasma collection centers to get some extra
GRIFOLS: Throw-back becoming a reality?After surpassing Fib 0.5, it looks like the stock is heading towards 0.382 level (21.81). Right now the company is immersed in a share repurchase program since 12/03/2021 and it has already acquired 19.23% of its €125 million valued shares objective. Maybe the company's financial advisers are playin
GRIFOLS: Results day coming on Feb 26. Then to the moon?68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021.
If GRLS results are positive or better than expected (speciall
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GRFS5271380
Grifols Escrow Issuer SA 4.75% 15-OCT-2028Yield to maturity
6.54%
Maturity date
Oct 15, 2028
XS239300189
GRIFOLS S.A. 21/28 REGSYield to maturity
5.53%
Maturity date
Oct 15, 2028
XS207764639
GRIFOLS 19/27 REGSYield to maturity
3.46%
Maturity date
Nov 15, 2027
See all GRFE bonds
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on AQUISEU exchange Grifols SA stocks are traded under the ticker GRFE.
We've gathered analysts' opinions on Grifols SA future price: according to them, GRFE price has a max estimate of 23.00 EUR and a min estimate of 9.00 EUR. Watch GRFE chart and read a more detailed Grifols SA stock forecast: see what analysts think of Grifols SA and suggest that you do with its stocks.
GRFE reached its all-time high on Feb 21, 2020 with the price of 34.310 EUR, and its all-time low was 6.370 EUR and was reached on Mar 6, 2024. View more price dynamics on GRFE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track Grifols SA financials in yearly and quarterly reports right on TradingView.
Grifols SA is going to release the next earnings report on Jul 29, 2025. Keep track of upcoming events with our Earnings Calendar.
GRFE earnings for the last quarter are 0.14 EUR per share, whereas the estimation was 0.14 EUR resulting in a 0.74% surprise. The estimated earnings for the next quarter are 0.20 EUR per share. See more details about Grifols SA earnings.
Grifols SA revenue for the last quarter amounts to 1.79 B EUR, despite the estimated figure of 1.75 B EUR. In the next quarter, revenue is expected to reach 1.92 B EUR.
GRFE net income for the last quarter is 59.73 M EUR, while the quarter before that showed 68.97 M EUR of net income which accounts for −13.40% change. Track more Grifols SA financial stats to get the full picture.
Grifols SA dividend yield was 0.00% in 2024, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 30, 2025, the company has 23.83 K employees. See our rating of the largest employees — is Grifols SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Grifols SA EBITDA is 1.67 B EUR, and current EBITDA margin is 21.66%. See more stats in Grifols SA financial statements.
Like other stocks, GRFE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Grifols SA stock right from TradingView charts — choose your broker and connect to your account.